Arvinas (ARVN) Gains from Investment Securities (2017 - 2018)
Arvinas (ARVN) posted quarterly Gains from Investment Securities of -$2516.0 for Q2 2018, down 72.68% year-over-year from -$9210.6 in Q2 2017, and down 101.28% quarter-over-quarter from $196295.0 in Q1 2018.
Powered by 
Analysis
Arvinas (ARVN) Gains from Investment Securities (2017 - 2018) Analysis & Trends
Arvinas' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$2516.0 for Q2 2018.
- In Q2 2018, Gains from Investment Securities fell 72.68% year-over-year to -$2516.0; the TTM figure through Mar 2019 stood at -$2516.0 (down 101.31% YoY), while the FY2018 annual figure was $193779.0, up 3400.61% from the prior year.
- Gains from Investment Securities for Q2 2018 stood at -$2516.0, down from $196295.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $196295.0 in Q1 2018, with the low at -$2516.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | -2,516.00 |
| Mar 31, 2018 | 196,295.00 |
| Dec 31, 2017 | -1,533.00 |
| Sep 30, 2017 | -1,546.00 |
| Jun 30, 2017 | -1,457.00 |
| Mar 31, 2017 | -1,335.00 |